Development and integration of validated, inexpensive, non-invasive, and reliable fluid and imaging biomarkers are critical to advance neurodegenerative and neuro-immunological drug candidates through clinical trials.

Built to provide cutting-edge insights across emerging biomarker technologies and address the current translational bottleneck hindering your pipeline’s success: the inaugural Fluid & Imaging Biomarkers in Neuroscience Summit is an unrivaled new opportunity to evaluate the latest biomarker research across AD, PD, MS & ALS, in one highly focused forum.

Unite with translational experts and biomarker specialists from the likes of Biogen, Eli Lilly, and Janssen to engage in forward-thinking discussions to meaningfully advance biomarker assessments of neurodegenerative and neuroinflammatory disease-modifying therapeutics.